Who we are
Xcellomics is a partnership between Exscientia and the University of Oxford Target Discovery Institute (TDI). The strategy and scientific decisions of Xcellomics are overseen and governed by the Board and Scientific Committee.
How it works
Academics worldwide are invited to submit their phenotypic assays through calls for proposals on diseases and phenotypes of interest. Submitted projects will be reviewed quarterly and selected for development by the Xcellomics Scientific Committee and Board using pre-defined criteria including disease relevance and novelty. Successful projects will retain co-ownership of intellectual property, receive a detailed screening report that includes confirmed hits, and may be eligible to receive milestone payments.
